Roles of a prostaglandin E-type receptor, EP3, in upregulation of matrix metalloproteinase-9 and vascular endothelial growth factor during enhancement of tumor metastasis

Cancer Science

Volumn 100, Issue 12, 2009, Pages 2318-2324

  Amano, Hideki ^a   Ito, Yoshiya ^a   Suzuki, Tastunori ^a   Kato, Shintaro ^a   Matsui, Yoshio ^a   Ogawa, Fumihiro ^a   Murata, Takahiko ^b   Sugimoto, Yukihiko ^c   Senior, Robert ^d   Kitasato, Hidero ^e   Hayashi, Izumi ^f   Satoh, Yukitoshi ^a   Narumiya, Shuh ^b   Majima, Masataka ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY FACULTY OF MEDICINE   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d BARNES JEWISH HOSPITAL   (United States)

^e School of Allied Health Sciences   (Japan)

^f NIHON PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; ACETYLSALICYLIC ACID; GELATINASE A; GELATINASE B; MESSENGER RNA; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; DOWN REGULATION; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; LEWIS CARCINOMA; LUNG CARCINOMA; LUNG METASTASIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION;

ANIMALS; ANTIGENS, CD31; CYCLOOXYGENASE 2; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; NITROBENZENES; RECEPTORS, PROSTAGLANDIN E; SULFONAMIDES; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70649106223     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01322.x     Document Type: Article

References (33)

1. Filder IJ, Ellis LM. The implication of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994, 79:185-8.
2. Folgueras AR, Pendás AM, Sánchez LM. Matrix metalloproteinase in cancer: from new function to improved inhibition strategies. Int J Dev Biol 2004, 48:411-24.
3. Smalley W, Dubois RN. Colorectal cancer and non-steroidal anti-inflammatory drugs. Adv Pharmacol 1997, 39:1-20.
4. Tsujii M, Kawano S, Dubois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997, 94:3336-40.
5. Narayanan BA, Narayanan NK, Pittman B. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model. Clin Cancer Res 2004, 10:7727-37.
6. Herschman H. Prostaglandin synthase 2. Biochim Biophys Acta 1996, 1299:125-40.
7. Sheng H, Shao MK, Washington MK. Prostaglandin E2 increases growth and mobility of colorectal carcinoma cells. J Biol Chem 2000, 276:18075-81.
8. Bunachanan FG, Wang F, Bargiacchi F, Dubois RN. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 2003, 278:35451-7.
9. Pai R, Nakamura T, Moon S. Prostaglandins promote colon cancer cell invasion: signaling by cross-talk between distinct growth factor receptors. FASEB J 2003, 17:1640-7.
10. Sugimoto Y, Narumiya S. Prostaglandin E receptor. J Biol Chem 2008, 282:11613-7.
11. Amano H, Hayashi I, Endo H. Host prostaglandin E2-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J Exp Med 2003, 197:221-32.
12. Matsuyama Y, Takao S, Aikou T. Comparison of matrix metalloproteinase expression between primary tumors with or without liver metastasis in pancreatic and colorectal carcinoma. J Surg Oncol 2002, 80:105-10.
13. Yen J-H, Khayrullina T, Ganea D. PGE2-induced metalloproteinase-9 is essential for dendritic cell migration. Blood 2008, 111:260-70.
14. Mayoral R, Fernández-Martínez A, Boscá L. Prostaglandin E2 promotes migration and adhesion in hepatocellular carcinoma cells. Carcinogenesis 2005, 26:753-61.
15. Suzawa T, Miyaura C, Inada M. The role of prostaglandin E receptor subtypes (EP1, EP2, EP3 and EP4) in bone resorption: an analysis using specific agonists for respective EPs. Endocrinology 2000, 141:1554-9.
16. Fujita M, Hayashi I, Yamashina S. Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth. Carcinogenesis 2005, 26:271-9.
17. Ikeda Y, Hayashi I, Kamoshita E. Host stromal bradikinin B2 receptor signaling facilitates tumor-associated angiogenesis and tumor growth. Cancer Res 2004, 64:5178-85.
18. Kamoshita E, Ikeda Y, Fujita M. Recruitment of a prostaglandin E receptor subtype, EP3-expressing bone marrow cells is crucial in wound-induced angiogenesis. Am J Pathol 2006, 169:1458-72.
19. Zuker S, Vacirca J. Role of metalloproteinase (MMPs) in colorectal cancer. Cancer Metastasis Review 2004, 23:101-17.
20. Pei D. Matrix metalloproteinase target protease-activated receptors on the tumor cell surface. Cancer Cell 2002, 7:207-8.
21. van Kempen LCL, Coussens L. MMP9 potentiates pulmonary metastasis formation. Cancer Cell 2002, 2:251-2.
22. Pan MR, Chuang LY, Hung WC. Non-steroidal anti-inflammatory drugs inhibit matrix metalloproteinase-2 expression via repression of transcription in the lung cancer. FEBS Lett 2001, 508:365-8.
23. Reckamp KL, Gardner BK, Figlin RA. Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin. J Thorac Oncol 2008, 3:117-24.
24. Attiga FA, Fernandez PM, Weeraratna AT. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res 2000, 60:4629-37.
25. Kaplan RN, Riba RD, Zacharoulis S. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005, 438:820-7.
26. Ogawa F, Suzuki T, Oikawa A. Bone marrow-derived EP3-expression stromal cells enhance tumor-associated angiogenesis and tumor growth. Biochem Biophys Res Commun 2009, 382:720-5.
27. Amano H, Ando K, Minamida S. Adenylate cyclase/protein kinase A signaling pathway enhances angiogenesis through induction of vascular endothelial growth factor in vivo. Jpn J Pharmacol 2001, 87:181-8.
28. Hahm ER, Gho YS, Park S. Synthetic curcumin analogs inhibit activator protein-1 transcription and tumor-induced angiogenesis. BBRC 2004, 321:337-44.
29. Uzzo RG, Crispen PL, Golovine K. Diverse effects of zinc on NF-γB and AP-1 transcription factors: implication for prostate cancer progression. Carcinogenesis 2006, 27:1980-90.
30. Callejas NA, Casado M, Díaz-Guerra MJM. Expression of cyclooxygenase-2 promotes the release of matrix metaloproteinase-2 and -9 in fetal rat hepatocytes. Hepatology 2001, 33:860-7.
31. Zhang Y, DeWitt DL, McNeely TB. Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2, and metalloproteinase. J Clin Invest 1997, 99:894-900.
32. DiBattista JA, Martel-Pelletier J, Fujimoto N. Prostaglandins E2 and E1 inhibit cytokine-induced metalloprotease expression in human synovial fibroblasts. Mediation by cyclic-AMP signalling pathway. Lab Invest 1994, 71:270-8.
33. Dormond O, Bezzi M, Mariotti A. Prostaglandin E2 promotes integrin αvβ3-dependent endothelial cell adhesion, Rac-activation and spreading through cAMP/PKA-dependent signaling. J Biol Chem 2002, 277:45838-46.